The role of organic anion transporters in diagnosing liver diseases by magnetic resonance imaging

Drug Metabolism and Disposition

Volumn 42, Issue 4, 2014, Pages 675-684

  Pastor, Catherine M ^a,b   Mul̈lhaupt, Beat ^c   Stieger, Bruno ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b INSERM   (France)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G5; ABC TRANSPORTER G8; BILE SALT EXPORT PUMP; BREAST CANCER RESISTANCE PROTEIN; BROMSULFOPHTHALEIN; CARRIER PROTEIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADOXETIC ACID; MEBROFENIN TC 99M; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 6; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 3; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER B; PROTEIN SLC22A10; PROTEIN SLC22A9; PROTEIN SLCO22A8; RIFAMPICIN; RITONAVIR; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; UNCLASSIFIED DRUG;

ANION EXCHANGE; BINDING AFFINITY; BINDING SITE; CELL MEMBRANE TRANSPORT; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; HUMAN; LIVER DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BIOLOGICAL TRANSPORT; CONTRAST MEDIA; DRUG INTERACTIONS; HUMANS; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; ORGANIC ANION TRANSPORTERS; RADIOPHARMACEUTICALS;

EID: 84896118430     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.055707     Document Type: Review

References (129)

1. Annet L, Materne R, Danse E, Jamart J, Horsmans Y, and Van Beers BE (2003) Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 229:409-414. (Pubitemid 37310826)
2. Bae KE, Kim SY, Lee SS, Kim KW, Won HJ, Shin YM, Kim PN, and Lee MG (2012) Assessment of hepatic function with Gd-EOB-DTPA-enhanced hepatic MRI. Dig Dis 30: 617-622.
3. Bar-Meir S, Baron J, Seligson U, Gottesfeld F, Levy R, and Gilat T (1982) 99mTc-HIDA cholescintigraphy in Dubin-Johnson and Rotor syndromes. Radiology 142:743-746. (Pubitemid 12180963)
4. Bennink RJ, Dinant S, Erdogan D, Heijnen BH, Straatsburg IH, van Vliet AK, and van Gulik TM (2004) Preoperative assessment of postoperative remnant liver function using hepatobiliary scintigraphy. J Nucl Med 45:965-971. (Pubitemid 47611683)
5. Bennink RJ, Tulchinsky M, de Graaf W, Kadry Z, and van Gulik TM (2012) Liver function testing with nuclear medicine techniques is coming of age. Semin Nucl Med 42:124-137.
6. Bioulac-Sage P, Cubel G, Taouji S, Scoazec JY, Leteurtre E, Paradis V, Sturm N, Nhieu JT, Wendum D, and Bancel B, et al. (2012) Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes. Am J Surg Pathol 36:1691-1699.
7. Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, Laurent C, Blanc JF, Cubel G, and Trillaud H, et al. (2009) Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 50:481-489.
8. Boyer JL, Graf J, and Meier PJ (1992) Hepatic transport systems regulating pHi, cell volume, and bile secretion. Annu Rev Physiol 54:415-438.
9. Briz O, Romero MR, Martinez-Becerra P, Macias RI, Perez MJ, Jimenez F, San Martin FG, and Marin JJ (2006) OATP8/1B3-mediated cotransport of bile acids and glutathione: an export pathway for organic anions from hepatocytes? J Biol Chem 281:30326-30335. (Pubitemid 44582086)
10. Bruix J and Sherman M; American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020-1022.
11. Burckhardt G (2012) Drug transport by Organic Anion Transporters (OATs). Pharmacol Ther 136:106-130.
12. Cascorbi I (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457-473.
13. Cascorbi I and Haenisch S (2010) Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol Biol 596:95-121.
14. Castera L (2012) Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 142:1293-1302, e4.
15. Chen ZS and Tiwari AK (2011) Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J 278:3226-3245.
16. Chow EC and Pang KS (2013) Why we need proper PBPK models to examine intestine and liver oral drug absorption. Curr Drug Metab 14:57-79.
17. Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, Lai Y, Matsson P, Moss A, Nagar S, and Rosania GR, et al.; International Transporter Consortium (2013) Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther 94:126-141.
18. Clavien PA, Oberkofler CE, Raptis DA, Lehmann K, Rickenbacher A, and El-Badry AM (2010) What is critical for liver surgery and partial liver transplantation: size or quality? Hepatology 52:715-729.
19. Conn HO (1981) A peek at the Child-Turcotte classification. Hepatology 1:673-676.
20. Daali Y, Millet P, Dayer P, and Pastor CM (2013) Evidence of drug-drug interactions through uptake and efflux transport systems in rat hepatocytes: implications for cellular concentrations of competing drugs. Drug Metab Dispos 41:1548-1556.
21. de Graaf W, Bennink RJ, Veteläinen R, and van Gulik TM (2010) Nuclear imaging techniques for the assessment of hepatic function in liver surgery and transplantation. J Nucl Med 51:742-752.
22. de Graaf W, Häusler S, Heger M, van Ginhoven TM, van Cappellen G, Bennink RJ, Kullak-Ublick GA, Hesselmann R, van Gulik TM, and Stieger B (2011) Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol 54:738-745.
23. de Liguori Carino N, O'Reilly DA, Dajani K, Ghaneh P, Poston GJ, and Wu AV (2009) Perioperative use of the LiMON method of indocyanine green elimination measurement for the prediction and early detection of post-hepatectomy liver failure. Eur J Surg Oncol 35:957-962.
24. Deo AK, Prasad B, Balogh L, Lai Y, and Unadkat JD (2012) Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry. Drug Metab Dispos 40:852-855.
25. European Association for the Study of the Liver (2011) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 55:245-264.
26. Esteller A (2008) Physiology of bile secretion. World J Gastroenterol 14:5641-5649.
27. Fahrmayr C, Fromm MF, and König J (2010) Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. Drug Metab Rev 42:380-401.
28. Franke RM, Gardner ER, and Sparreboom A (2010) Pharmacogenetics of drug transporters. Curr Pharm Des 16:220-230.
29. Ghibellini G, Leslie EM, Pollack GM, and Brouwer KL (2008) Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm Res 25:1851-1860.
30. Gotoh K, Yamada T, Ishikawa O, Takahashi H, Eguchi H, Yano M, Ohigashi H, Tomita Y, Miyamoto Y, and Imaoka S (2009) A novel image-guided surgery of hepatocellular carcinoma by indocyanine green fluorescence imaging navigation. J Surg Oncol 100:75-79.
31. Grazioli L, Morana G, Kirchin MA, and Schneider G (2005) Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 236:166-177. (Pubitemid 40853309)
32. Gu X and Manautou JE (2010) Regulation of hepatic ABCC transporters by xenobiotics and in disease states. Drug Metab Rev 42:482-538.
33. Hagenbuch B and Gui C (2008) Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38:778-801.
34. Hagenbuch B and Stieger B (2013) The SLCO (former SLC21) superfamily of transporters. Mol Aspects Med 34:396-412.
35. Ho RH, Leake BF, Kilkenny DM, Meyer Zu Schwabedissen HE, Glaeser H, Kroetz DL, and Kim RB (2010) Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenet Genomics 20:45-57.
36. Hoekstra LT, de Graaf W, Nibourg GA, Heger M, Bennink RJ, Stieger B, and van Gulik TM (2013) Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg 257:27-36.
37. Hofmann AF (2009) Bile acids: trying to understand their chemistry and biology with the hope of helping patients. Hepatology 49:1403-1418.
38. Horak W, Grabner G, and Paumgartner G (1973) Inhibition of bile salt-independent bile formation by indocyanine green. Gastroenterology 64:1005-1012.
39. Huppertz A, Breuer J, Fels LM, Schultze-Mosgau M, Sutter G, Klein S, Frericks B, Hamm B, and Wagner M (2011) Evaluation of possible drug-drug interaction between gadoxetic acid and erythromycin as an inhibitor of organic anion transporting peptides (OATP). J Magn Reson Imaging 33:409-416.
40. Ieiri I, Higuchi S, and Sugiyama Y (2009) Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5:703-729.
41. Imamura H, Sano K, Sugawara Y, Kokudo N, and Makuuchi M (2005) Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg 12:16-22. (Pubitemid 40378835)
42. Jacquemin E, Hagenbuch B, Stieger B, Wolkoff AW, and Meier PJ (1994) Expression cloning of a rat liver Na(+)-independent organic anion transporter. Proc Natl Acad Sci USA 91:133-137. (Pubitemid 24018657)
43. Jang YJ, Cho SH, Bae JH, Kim GC, Ryeom H, Kim HJ, Shin KM, and Lee HJ (2013) Non-invasive assessment of hepatic fibrosis using gadoxetate-disodium- enhanced 3T MRI. Ann Hepatol 12:926-934.
44. Jia J, Puls D, Oswald S, Jedlitschky G, Kühn JP, Weitschies W, Hosten N, Siegmund W, and Keiser M (2014) Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic Acid. Invest Radiol 49:78-86.
45. Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, and Galetin A, et al. (2012) Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40:1007-1017.
46. Kalliokoski A and Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693-705.
47. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, and Artursson P (2012) Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem 55:4740-4763.
48. Kato N, Yokawa T, Tamura A, Heshiki A, Ebert W, and Weinmann HJ (2002) Gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid interaction with clinical drugs in rats. Invest Radiol 37:680-684. (Pubitemid 35429188)
49. Katsube T, Okada M, Kumano S, Hori M, Imaoka I, Ishii K, Kudo M, Kitagaki H, and Murakami T (2011) Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol 46:277-283.
50. Kawaguchi Y, Ishizawa T, Miyata Y, Yamashita S, Masuda K, Satou S, Tamura S, Kaneko J, Sakamoto Y, and Aoki T, et al. (2013) Portal uptake function in veno-occlusive regions evaluated by real-time fluorescent imaging using indocyanine green. J Hepatol 58:247-253.
51. Keiding S (2012) Bringing physiology into PET of the liver. J Nucl Med 53:425-433.
52. Keppler D (2011) Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handbook Exp Pharmacol 201:299-323.
53. Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, Koda W, Kobayashi S, Gabata T, Zen Y, and Yamashita T, et al. (2011) The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 21:2056-2066.
54. Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W, Kozaka K, Yoneda N, Yamashita T, and Kaneko S, et al. (2010) Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging - correlation with molecular transporters and histopathologic features. Radiology 256:817-826.
55. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, and Tamai I (2003) Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 306:703-708. (Pubitemid 36886171)
56. Koepsell H (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med 34:413-435.
57. König J (2011) Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms. Handbook Exp Pharmacol 201:1-28.
58. Kusuhara H (2013) Imaging in the study of membrane transporters. Clin Pharmacol Ther 94:33-36.
59. LaRusso NF, Hoffman NE, Hofmann AF, and Korman MG (1975) Validity and sensitivity of an intravenous bile acid tolerance test in patients with liver disease. N Engl J Med 292:1209-1214.
60. Lee YJ, Lee JM, Lee JE, Lee KB, Lee ES, Yoon JH, Yu MH, Baek JH, Shin CI, and Han JK, et al. (2014) MR elastography for noninvasive assessment of hepatic fibrosis: Reproducibility of the examination and reproducibility and repeatability of the liver stiffness value measurement. J Magn Reson Imaging 39:326-331.
61. Leonhardt M, Keiser M, Oswald S, Kühn J, Jia J, Grube M, Kroemer HK, Siegmund W, and WeitschiesW (2010) Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 38:1024-1028.
62. Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ, and Stieger B (2009) Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol 296:C570-C582.
63. Levesque E, Saliba F, Benhamida S, Ichaï P, Azoulay D, Adam R, Castaing D, and Samuel D (2009) Plasma disappearance rate of indocyanine green: a tool to evaluate early graft outcome after liver transplantation. Liver Transpl 15:1358-1364.
64. Lewin M, Handra-Luca A, Arrivé L, Wendum D, Paradis V, Bridel E, Fléjou JF, Belghiti J, Tubiana JM, and Vilgrain V (2006) Liver adenomatosis: classification of MR imaging features and comparison with pathologic findings. Radiology 241:433-440. (Pubitemid 44632889)
65. Li L, Lee TK, Meier PJ, and Ballatori N (1998) Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter. J Biol Chem 273:16184-16191. (Pubitemid 28311391)
66. Li L, Meier PJ, and Ballatori N (2000) Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol Pharmacol 58:335-340. (Pubitemid 30497477)
67. Mahagita C, Grassl SM, Piyachaturawat P, and Ballatori N (2007) Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am J Physiol Gastrointest Liver Physiol 293:G271-G278. (Pubitemid 47105195)
68. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, and ter Borg PC (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31:864-871. (Pubitemid 30169932)
69. Marin JJ, Mangas D, Martinez-Diez MC, El-Mir MY, Briz O, and Serrano MA (2003) Sensitivity of bile acid transport by organic anion-transporting polypeptides to intracellular pH. Biochim Biophys Acta 1611:249-257. (Pubitemid 36351454)
70. Martinez-Becerra P, Briz O, Romero MR, Macias RI, Perez MJ, Sancho-Mateo C, Lostao MP, Fernandez-Abalos JM, and Marin JJ (2011) Further characterization of the electrogenicity and pH sensitivity of the human organic anion-transporting polypeptides OATP1B1 and OATP1B3. Mol Pharmacol 79:596-607.
71. Materne R, Smith AM, Peeters F, Dehoux JP, Keyeux A, Horsmans Y, and Van Beers BE (2002) Assessment of hepatic perfusion parameters with dynamic MRI. Magn Reson Med 47:135-142. (Pubitemid 34019702)
72. Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK, Nussler N, Eichelbaum M, Meier PJ, and Stieger B (2006) Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 44:62-74. (Pubitemid 44049139)
73. Millet P, Moulin M, Stieger B, Daali Y, and Pastor CM (2011) How organic anions accumulate in hepatocytes lacking Mrp2: evidence in rat liver. J Pharmacol Exp Ther 336:624-632.
74. Mittur A, Wolkoff AW, and Kaplowitz N (2002) The thiol sensitivity of glutathione transport in sidedness-sorted basolateral liver plasma membrane and in Oatp1-expressing HeLa cell membrane. Mol Pharmacol 61:425-435. (Pubitemid 34112818)
75. Müllhaupt B, Durand F, Roskams T, Dutkowski P, and Heim M (2011) Is tumor biopsy necessary? Liver Transpl 17 (Suppl 2):S14-S25.
76. Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, Taura K, Yasuchika K, Nitta T, and Ikai I, et al. (2009) Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 44:793-798.
77. Nassif A, Jia J, Keiser M, Oswald S, Modess C, Nagel S, Weitschies W, Hosten N, Siegmund W, and Kühn JP (2012) Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging. Radiology 264:741-750.
78. Neyt S, Huisman MT, Vanhove C, De Man H, Vliegen M, Moerman L, Dumolyn C, Mannens G, and De Vos F (2013) In vivo visualization and quantification of (Disturbed) Oatp-mediated hepatic uptake and Mrp2-mediated biliary excretion of 99mTc-mebrofenin in mice. J Nucl Med 54:624-630.
79. Niemi M, Pasanen MK, and Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157-181.
80. Nies AT, Niemi M, Burk O, Winter S, Zanger UM, Stieger B, Schwab M, and Schaeffeler E (2013) Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med 5:1-11.
81. Nies AT, Schwab M, and Keppler D (2008) Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol 4:545-568. (Pubitemid 351890738)
82. Nilsson H, Blomqvist L, Douglas L, Nordell A, Jacobsson H, Hagen K, Bergquist A, and Jonas E (2013) Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis. J Magn Reson Imaging DOI:10.1002/jmri.24250 [published ahead of print].
83. Nozawa T, Imai K, Nezu J, Tsuji A, and Tamai I (2004) Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 308:438-445. (Pubitemid 38134202)
84. Ogasawara K, Terada T, Katsura T, Hatano E, Ikai I, Yamaoka Y, and Inui K (2010) Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab Pharmacokinet 25: 190-199.
85. Paradis V (2010) Benign liver tumors: an update. Clin Liver Dis 14:719-729.
86. Pastor CM, Planchamp C, Pochon S, Lorusso V, Montet X, Mayer J, Terrier F, and Vallée J-P (2003) Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation. Radiology 229:119-125. (Pubitemid 37152113)
87. Pastor CM, Wissmeyer M, and Millet P (2013) Concentrations of Gd-BOPTA in cholestatic fatty rat livers: role of transport functions through membrane proteins. Contrast Media Mol Imaging 8:147-156.
88. Pfeifer ND, Goss SL, Swift B, Ghibellini G, Ivanovic M, Heizer WD, Gangarosa LM, and Brouwer KL (2013) Effect of Ritonavir on (99m)Technetium- Mebrofenin Disposition in Humans: A semi-PBPK modeling and in vitro approach to predict transporter-mediated DDIs. CPT Pharmacometrics Syst Pharmacol 2:e20.
89. Pfeifer ND, Hardwick RN, and Brouwer KL (2014) Role of hepatic efflux transporters in regulating systemic and hepatocyte exposure to xenobiotics. Annu Rev Pharmacol Toxicol 54:509-535.
90. Planchamp C, Hadengue A, Stieger B, Bourquin J, Vonlaufen A, Frossard J-L, Quadri R, Becker CD, and Pastor CM (2007) Function of both sinusoidal and canalicular transporters controls the concentration of organic anions within hepatocytes. Mol Pharmacol 71:1089-1097. (Pubitemid 46457012)
91. Planchamp C, Montet X, Frossard J-L, Quadri R, Stieger B, Meier PJ, Ivancevic MK, Vallée J-P, Terrier F, and Pastor CM (2005a) Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers. Invest Radiol 40:187-194. (Pubitemid 40393229)
92. Planchamp C, Pastor CM, Balant L, Becker CD, Terrier F, and Gex-Fabry M (2005b) Quantification of Gd-BOPTA uptake and biliary excretion from dynamic MRI in rat livers: model validation with 153Gd-BOPTA. Invest Radiol 40:705-714. (Pubitemid 41546837)
93. Poynard T, Ngo Y, Perazzo H, Munteanu M, Lebray P, Moussalli J, Thabut D, Benhamou Y, and Ratziu V (2011) Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol (N Y) 7:445-454.
94. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, and Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646-649.
95. Renner EL (1995) Liver function tests. Baillieres Clin Gastroenterol 9:661-677.
96. Rizwan AN and Burckhardt G (2007) Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 24:450-470. (Pubitemid 46295167)
97. Ronot M, Bahrami S, Calderaro J, Valla DC, Bedossa P, Belghiti J, Vilgrain V, and Paradis V (2011) Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology 53:1182-1191.
98. Rostami-Hodjegan A (2012) Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther 92:50-61.
99. Roth M, Obaidat A, and Hagenbuch B (2012) OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 165:1260-1287.
100. Sakka SG (2007) Assessing liver function. Curr Opin Crit Care 13:207-214.
101. Salvolini L, Urbinati C, Valeri G, Ferrara C, and Giovagnoni A (2012) Contrast-enhanced MR cholangiography (MRCP) with GD-EOB-DTPA in evaluating biliary complications after surgery. Radiol Med (Torino) 117:354-368.
102. Scharf J, Zapletal C, Hess T, Hoffmann U, Mehrabi A, Mihm D, Hoffmann V, Brix G, Kraus T, and Richter GM, et al. (1999) Assessment of hepatic perfusion in pigs by pharmacokinetic analysis of dynamic MR images. J Magn Reson Imaging 9:568-572. (Pubitemid 29194296)
103. Schmidt S, Denys A, and Pastor CM (2013) Portal uptake function in veno-occlusive regions evaluated by real-time fluorescent imaging using indocyanine green. J Hepatol 59:631-632.
104. Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, Fichtner-Feigl S, Lorf T, Goralcyk A, and Hörbelt R, et al. (2012) Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 255:405-414.
105. Shin HJ, Lee CH, Lee SS, Song IS, and Shin JG (2010) Identification of genetic polymorphisms of human OAT1 and OAT2 genes and their relationship to hOAT2 expression in human liver. Clin Chim Acta 411:99-105.
106. Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, and Sugiyama Y (2013) Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 34:45-78.
107. Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, and Figg WD (2010) Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol 44:152-167.
108. Sodani K, Patel A, Kathawala RJ, and Chen ZS (2012) Multidrug resistance associated proteins in multidrug resistance. Chin J Cancer 31:58-72.
109. Sommer WH, Sourbron S, Huppertz A, Ingrisch M, Reiser MF, and Zech CJ (2012) Contrast agents as a biological marker in magnetic resonance imaging of the liver: conventional and new approaches. Abdom Imaging 37:164-179.
110. Stieger B, Heger M, de Graaf W, Paumgartner G, and van Gulik T (2012) The emerging role of transport systems in liver function tests. Eur J Pharmacol 675:1-5.
111. Stieger B and Meier PJ (2011) Pharmacogenetics of drug transporters in the enterohepatic circulation. Pharmacogenomics 12:611-631.
112. Stockmann M, Lock JF, Malinowski M, Niehues SM, Seehofer D, and Neuhaus P (2010) The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford) 12:139-146.
113. 11C]telmisartan. Mol Pharm 8:1789-1798.
114. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, and Tsuji A (2001) Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res 18:1262-1269. (Pubitemid 32846318)
115. Tschirch FT, Struwe A, Petrowsky H, Kakales I, Marincek B, and Weishaupt D (2008) Contrastenhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 18:1577-1586.
116. Tsuboyama T, Onishi H, Kim T, Akita H, Hori M, Tatsumi M, Nakamoto A, Nagano H, Matsuura N, and Wakasa K, et al. (2010) Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging - correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 255:824-833.
117. Tucker TG, Milne AM, Fournel-Gigleux S, Fenner KS, and Coughtrie MW (2012) Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum. Biochem Pharmacol 83:279-285.
118. Van Beers BE, Pastor CM, and Hussain HK (2012) Primovist, Eovist: what to expect? J Hepatol 57:421-429.
119. van Montfoort JE, Stieger B, Meijer DKF, Weinmann H-J, Meier PJ, and Fattinger KE (1999) Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 290:153-157. (Pubitemid 29302315)
120. Verloh N, Haimerl M, Rennert J, Müller-Wille R, Nießen C, Kirchner G, Scherer MN, Schreyer AG, Stroszczynski C, and Fellner C, et al. (2013) Impact of liver cirrhosis on liver enhancement at Gd-EOB-DTPA enhanced MRI at 3 Tesla. Eur J Radiol 82:1710-1715.
121. Visentin M, Chang MH, Romero MF, Zhao R, and Goldman ID (2012) Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1). Mol Pharmacol 81:134-142.
122. Wang L and Sweet DH (2013) Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease. AAPS J 15:53-69.
123. Watanabe T, Kusuhara H, and Sugiyama Y (2010) Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J Pharmacokinet Pharmacodyn 37:575-590.
124. Wlcek K and Stieger B (2013) ATP-binding cassette transporters in liver. Biofactors DOI: 10.1002/biof.1136 [published ahead of print].
125. Yamada A, Hara T, Li F, Fujinaga Y, Ueda K, Kadoya M, and Doi K (2011) Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging. Radiology 260:727-733.
126. Yoshida K, Maeda K, and Sugiyama Y (2013) Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. Annu Rev Pharmacol Toxicol 53:581-612.
127. Yumoto Y, Yagi T, Sato S, Nouso K, Kobayashi Y, Ohmoto M, Yumoto E, Nagaya I, and Nakatsukasa H (2010) Preoperative estimation of remnant hepatic function using fusion images obtained by (99m)Tc-labelled galactosyl-human serum albumin liver scintigraphy and computed tomography. Br J Surg 97:934-944.
128. Zaïr ZM, Eloranta JJ, Stieger B, and Kullak-Ublick GA (2008) Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics 9:597-624. (Pubitemid 351803919)
129. Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, Leteurtre E, Paradis V, and Michalak S, et al. (2006) Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43:515-524.